502171-71-3

Downstream Products

• 711022-21-8 [5-(4-{2-[2-(4-hydroxy-piperidin-1-yl)-ethylcarbamoyl]-1-methyl-1H-imidazol-4-ylcarbamoyl}-phenylcarbamoyl)-1-methyl-1H-pyrrol-3-yl]-carbamic acid tert-butyl ester 
• 758727-15-0 1-(2-hydroxyethyl)-4-{2-[1-methyl-4-(4-(4-amino-1-methyl-2-pyrrolecarboxamido)-1-benzamido)-2-imidazolecarboxamido]ethyl}piperidine 

Relevant academic research and scientific papers

Parallel synthesis and evaluation of 132 (+)-1,2,9,9a-tetrahydrocyclopropa[c]benz[e]indol-4-one (CBI) analogues of CC-1065 and the duocarmycins defining the contribution of the DNA-binding domain

The solution-phase, parallel synthesis and evaluation of a library of 132 (+)-1,2,9,9a-tetrahydrocyclopropa[c]benz[e]indol-4-one (CBI) analogues of CC-1065 and the duocarmycins containing dimeric monocyclic, bicyclic, and tricyclic heteroaromatic replacements for the DNA-binding domain are described. This systematic study revealed clear trends in the structural requirements for observation of potent cytotoxic activity and DNA alkylation efficiency, the range of which spans a magnitude of ≥10 000-fold. Combined with related studies, these results highlight that the role of the DNA-binding domain goes beyond simply providing DNA-binding selectivity and affinity (10-100-fold enhancement in properties), consistent with the proposal that it contributes significantly to catalysis of the DNA alkylation reaction accounting for as much as an additional 1000-fold enhancement in properties.